Contribute Try STAT+ Today

Wakey-wakey, everyone. It’s Friday! You can sip your cup of stimulation with satisfaction this morning: You made it through another week. Nick Florko here, filling in for the great Ed Silverman. We are all out of exciting sipping choices here, so straight espresso will have to do. We are hopeful, however, that the afternoon may bring some more scintillating options: A tamarind espresso tonic, perhaps? Time will tell. Here are a few items of interest to get you through that last trudge before the weekend. …

The Food and Drug Administration expects to have a plan on Covid-19 boosters by early September, the Wall Street Journal reports. The plan is likely to lay out who should receive boosters and when, sources tell the Journal. Pfizer (PFE) is expected to ask the FDA this month for authorization to sell booster shots. Moderna (MRNA) is expected to do the same in September.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment